Sarah Rumple Mahan
Editor-In-Chief
Sarah Rumple Mahan is an award-winning veterinary writer and editor living in Denver, Colorado. Sarah has written for Today’s Veterinary Business since 2018, and she became the publication’s editor-in-chief in 2026. Reach her at smahan@navc.com.

Dechra has completed its acquisition of Gallant Pet, a U.S.-based animal health biotechnology company focused on developing ready-to-use mesenchymal stromal cell (MSC) therapies.
According to Dechra, the acquisition establishes a new therapeutic platform designed to treat chronic and complex conditions by working with a patient’s natural biological processes. The regenerative medicine pipeline features therapies designed to address multiple conditions and target the root causes of diseases across different animal species. The first innovation from the newly acquired portfolio is expected to reach the market as early as 2027.
Combining Gallant’s platform with Dechra’s global reach creates “a strong foundation to bring new treatment options to veterinarians and their patients,” said Dr. Cathy Knupp, Dechra’s chief scientific officer.
Financial terms of the transaction were not disclosed.
